Hospira Issues Voluntary Nationwide Recall


Hospira Issues Voluntary Nationwide Recall

Naloxone used to only be available in hospitals, but is now carried by many first responders and medical professionals, and is available without a prescription in certain areas, all of which is in response to the nationwide opioid epidemic. The FDA announcement said some of the drug may have then been further distributed at the retail level.

The opioid overdose drug Naloxone has been recalled.

Users can inspect the Naloxone before it is administered to a person by looking for particulate matter near the syringe and looking for discoloration before it is administered. Those units were sent to wholesalers, distributors and hospitals in the US, Puerto Rico and Guam from February 2017 to February 2018. The recall was issued because embedded and loose particulate matter on the syringe plunger may be present. "Hospira, Inc., has notified wholesalers/distributors/hospitals to arrange for return of any recalled product". There's a quick-acting antidote to save them called naloxone or Narcan.

When administered, Naloxone can quickly restore normal respiration to someone whose breathing has slowed or stopped due to opioids.

78 people die each day from opioid overdoses.

The voluntary recall by the Pfizer subsidiary is for Carpuject single-use cartridge syringe system (NDC 0409-1782-69) of naloxone hydrochloride injection, USP (lots 72680LL and 76510LL; 0.4 mg/mL, 1 mL in 2.5 mL doses for both lots). The data came from the fatal overdose from 31 states that produced reliable reports of drug-related causes of death.